The simultaneous use of PD‐1 and TIGIT now appears to be very promising because TIGIT inhibition or in combination with PD‐1 inhibition primarily works on NK cells to promote antitumor response and inhibit cancer progression.10 The gene discussed is TIGIT; the disease is cancer.